Angiotensin-converting-enzyme insertion/deletion polymorphism, ACE activity, and COVID-19: A rather controversial...

Area of Science:

• Genetics
• Cardiovascular Research
• Infectious Diseases

Background:

• The renin-angiotensin system plays a role in COVID-19 pathogenesis.
• The angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism's impact on COVID-19 risk is debated.
• Understanding genetic predispositions is crucial for managing COVID-19 severity.

Purpose of the Study:

• To investigate the association between ACE I/D genotype and COVID-19 disease prevalence and severity.
• To assess the correlation between ACE genotype, ACE activity, and COVID-19 outcomes.
• To explore potential mechanisms linking ACE genotype to severe COVID-19.

Main Methods:

• Retrospective case-control study involving 81 COVID-19 patients and 316 controls.
• Determination of ACE I/D genotype and ACE activity in all participants.
• Statistical analysis using generalized linear models and Poisson regression to estimate risk ratios.

Main Results:

• Patients with the ACE DD genotype had a nearly 2-fold increased risk of severe COVID-19 compared to ID and II individuals.
• D allele carriers showed a significantly higher risk of severe disease than I allele carriers.
• ACE activity was significantly lower in COVID-19 patients, particularly in those with the DD genotype, compared to controls.

Conclusions:

• The ACE DD genotype may predispose individuals to increased COVID-19 severity, potentially mediated by reduced ACE activity.
• A complex interplay between ACE polymorphism and ACE activity exists in COVID-19 patients.
• Findings support further research into ACE genotype-guided therapies, including ACE inhibitors and angiotensin receptor blockers, for COVID-19 management.